Committee opinion

Kinjo, M., Masuda, K., Nakamura, Y. et al. Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?. Int Urogynecol J 34, 853–859 (2023).
In this article the authors aimed to determine whether the presence of metabolic syndrome (MS) affects the efficacy of mirabegron in the treatment women with overactive bladder (OAB).
Efficacy of treatment with mirabegron 50 mg was compared between women with and without MS by using the OAB symptom score (OABSS) and a 3-day voiding diary before and 12 weeks after starting treatment…